Long term high flow heated oxygen treatment in COPD – lung function and physical ability

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review


Introduction: Long term oxygen therapy (LTOT) improves survival in patients with COPD with resting hypoxemia. Despite this, a progressive loss of lung function and physical ability is expected in COPD. The AIRVO device delivers nasal high flow (NHF) warmed and humidified oxygen-enriched air, 20-30 L/minute via the Optiflow interface to COPD patients in need of LTOT.Aim: To investigate the treatment effect of NHF on lung function, (Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC) in liters and percent, 6 minute walking test (6MWT) and modified MRC (mMRC) dyspnoea scores in COPD patients with resting hypoxemia over 12 months.Method: In this prospective, randomized controlled, one-year study, 200 COPD patients, all FEV1 GOLD class 4, treated with LTOT, were randomized to AIRVO-NHF (n=100) or usual care (n=100) between March 2013 and June 2015.Results: The two treatment groups are comparable in average days in study, age, gender, smoking status, pack years, BMI, FEV1 and FVC, L and %, 6MWT and number of exacerbations and admissions one year prior to study start, although controls had better mMRC at baseline. At 12 months, AIRVO-NHF patients had significantly more improved FEV1% (p<0.05) and 6MWT (p<0.05). After 3 months AIRVO-NHF patients had significantly more improved mMRC scores (p<0.05) with statistical significance of p<0.0001 after 12 months whether as change or absolute values.Conclusion: These results show a significant treatment effect in favor of AIRVO-NHF preventing decrease in FEV1, increasing 6MWT and mMRC score (in particular) in COPD patients in need of LTOT.
TidsskriftEuropean Respiratory Journal
Udgave nummersuppl 61
StatusUdgivet - 2017
BegivenhedERS International Congress 2017 - Milan, Italien
Varighed: 9 sep. 201713 sep. 2017


KonferenceERS International Congress 2017